Skip to main content

Table 2 Summary of response rate (RR) and disease control (DCR) between Del-19 and L858R

From: Differential efficacy of cisplatin plus pemetrexed between L858R and Del-19 in advanced EGFR-mutant non-squamous non-small cell lung cancer

  RR (%) p-value DCR (%) p-value
All patients (n = 78) 39.7   85.9  
EGFR mutation status
 Del-19 36.1 0.54 80.6 0.21
 L858R 42.9   90.5  
  1. Del-19 19 deletion; L858R Leu858Arg, EGFR epidermal growth factor receptor